Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.
Jean-Luc Van Laethem
No relevant relationships to disclose
Jacek Jassem
No relevant relationships to disclose
Volker Heinemann
No relevant relationships to disclose
Colin D. Weekes
No relevant relationships to disclose
John A. Bridgewater
Consultant or Advisory Role - Merck; Roche; Sanofi
Stefano Cascinu
No relevant relationships to disclose
Bohuslav Melichar
No relevant relationships to disclose
Marc Peeters
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Research Funding - Bayer
Paul J. Ross
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Other Remuneration - Celgene
Piotr Saramak
No relevant relationships to disclose
Marius Giurescu
Employment or Leadership Position - Bayer
Vittorio Luigi Garosi
Employment or Leadership Position - Bayer
Katrin Roth
Employment or Leadership Position - Bayer
Anke Schulz
Employment or Leadership Position - Bayer
Michael Teufel
Employment or Leadership Position - Bayer
Barrett H. Childs
Employment or Leadership Position - Bayer
Hanno Riess
Consultant or Advisory Role - Celgene; Merck; Roche; Sanofi